177Lu-PRRT治疗晚期胃肠神经内分泌肿瘤:IRST二期前瞻性研究10年随访
该开放标签、疾病导向的前瞻性二期研究纳入43例进展性转移性胃肠神经内分泌肿瘤患者,接受5个周期177Lu-DOTA-奥曲肽肽受体放射性核素治疗(每6至8周一次,每次3.7 GBq或5.5 GBq)。10年随访显示两组中位无进展生存期均为59.8个月,未观察到晚期血液学或肾毒性,肿瘤负荷(肝转移)和年龄是重要预后因素。
要点
- 43例患者中位随访118个月,18.5 GBq组与27.5 GBq组中位PFS均为59.8个月。
- 18.5 GBq组中位OS为71.0个月,27.5 GBq组为97.6个月(P=0.22)。
- 淋巴结进展患者的中位PFS和OS显著长于肝转移患者(P=0.02和P=0.04)。
核心结论
- 长期随访显示Lu-PRRT对晚期胃肠神经内分泌肿瘤安全有效,最重要的预后因素为肿瘤负荷(肝转移)和年龄。
- 作者认为Lu-PRRT应提供给早期疾病患者。
研究设计与样本
- 开放标签、疾病导向的前瞻性二期研究,2008年3月至2011年6月纳入43例进展性转移性胃肠神经内分泌肿瘤患者。
- 患者接受177Lu-DOTA-奥曲肽肽受体放射性核素治疗,每6至8周一次,共5个周期,每次剂量为3.7 GBq或5.5 GBq(即总剂量18.5 GBq或27.5 GBq)。
- 所有患者已知病灶的68镓-DOTA-肽PET/奥曲肽扫描均为阳性(鹿特丹量表评分3-4分)。
主要发现
- 43例患者(28例男性,15例女性)可评估,中位监测时间为118个月(范围12.6-139.6个月)。
- 18.5 GBq组中位无进展生存期为59.8个月(95%CI 14.3-79.6),27.5 GBq组为59.8个月(95%CI 23.4-82.0)。
- 18.5 GBq组中位总生存期为71.0个月(95%CI 46.1-107.3),27.5 GBq组为97.6个月(95%CI 64.3-未达到)(P=0.22)。
- 进展局限于淋巴结的患者中位无进展生存期和总生存期显著长于肝转移患者(无进展生存期P=0.02,总生存期P=0.04)。
- 治疗时年龄超过65岁对总生存期也有显著影响。
临床怎么用
- 作者认为Lu-PRRT应提供给早期疾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In March 2014, we reported the activity and safety of 177Lu-DOTA-octreotate peptide receptor radionuclide therapy (Lu-PRRT) at two different dosages (18.5 GBq and 27.5 GBq in 5 cycles) in patients with progressive metastatic gastrointestinal neuroendocrine tumors (GI-NETs). Disease control rate (DCR) and toxicity were addressed. Herein, we report the late toxicity, progression-free survival (PFS), and overall survival (OS) in the same cohort after a 10-year follow-up. METHODS: We conducted an open-label, disease-oriented prospective phase II trial. From March 2008 to June 2011, 43 patients received 3.7 GBq or 5.5 GBq of Lu-PRRT every 6 to 8 weeks, each cycle repeated 5 times. All patients showed 68Gallium-DOTA-peptide PET/Octreoscan® positivity (score 3-4 Rotterdam scale) in known lesions. Tumor burden was estimated radiologically. Time-to-event data (PFS and OS) were described using Kaplan-Meier curves and compared with the log-rank test. RESULTS: Forty-three patients (28 males and 15 females) were evaluable and were monitored for a median period of 118 months (range 12.6-139.6). Median PFS in patients receiving 18.5 GBq was 59.8 months (95% confidence interval [95% CI] 14.3-79.6), identical to that of patients treated with 27.5 GBq (59.8 months, 95% CI 23.4-82.0). Median OS was 71.0 months (95% CI 46.1-107.3) in the group who received 18.5 GBq and 97.6 months (95% CI 64.3-not reached) in the group treated with 27.5 GBq (P = 0.22). Patients with progression limited to lymph nodes showed significantly longer median PFS and OS than those with hepatic lesions (P = 0.02 for PFS and P = 0.04 for OS). Age over 65 years at the time of PRRT was also significant for OS. Of note, no late hematological or renal toxicity was observed in either group. CONCLUSIONS: The long-term follow-up of the IRST phase II study shows that Lu-PRRT is a safe and effective therapy for patients with advanced GI-NET, the most important prognostic factor being tumor burden, hepatic lesions, and age. We believe that Lu-PRRT should be offered to patients with early-stage disease.
引用
- Paganelli G, Sansovini M, Nicolini S, et al. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med Mol Imaging. 2020. PMID: 32472437. doi:10.1007/s00259-020-04873-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。